Sangui BioTech:

• Sales of USD 49,389 in first quarter
• Increase in quarterly result

Hamburg, October 29, 2025:
In the first three months of fiscal year 2026 (to 30/06/2026) Sangui BioTech International Inc. achieved revenues from royalty income of USD 49,389. In the same period of the previous year the comparable revenue amounted to USD 54,323. Due to lower revenues of the wound spray Granulox, the resulting royalty income in the first three-month period of the year decreased by 9% compared to the same period of the previous year.

Operating expenses decreased USD 1,912 or 6% to USD 32,828 during the first quarter. As a result of the above factors, the three-month operating result decreased USD 3,022 from USD 19,583 to of USD 16,561.

Due to the higher exchange rate of the US dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate gains from the valuation of loans denominated in EURO, a positive quarterly result of USD 10,517 occurred. Compared to the previous year, in which a loss of USD 20,717 was achieved in the comparable period, the quarterly result increased by USD 31,234.

Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the pink marketplace operated by OTC Markets Group Inc. Companies are current in their reporting and undergo an annual verification and management certification process. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.

For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
e-mail: info@sangui.de

Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

---